Which company produces durvalumab (durvalumab) and introduces its brand background?

Durvalumab (Durvalumab), trade name Imfinzi (Infinifer), is developed and produced by the global pharmaceutical company AstraZeneca (AstraZeneca). AstraZeneca is a multinational pharmaceutical company headquartered in the United Kingdom, focusing on the research and development of innovative drugs in the fields of oncology, cardiovascular, renal and metabolic diseases. As one of AstraZeneca's important layouts in the field of immuno-oncology treatment, durvalumab represents the company's continued innovation and development in tumor immunotherapy.

AstraZeneca's business in the Chinese market is also expanding. The company has established production bases in Wuxi and Taizhou, Jiangsu, and a China logistics center in Wuxi to support its operations and supply chain management in the Chinese market. The construction of these facilities reflects AstraZeneca's emphasis on the Chinese market and its localization strategy for its business in China.

Irvalumab was developed by MedImmune, a wholly-owned subsidiary of AstraZeneca, in2017, and was approved by the U.S.FDA in 2017 for the treatment of certain types of bladder cancer and lung cancer. The drug is a fully humanized anti-PD-L1 monoclonal antibody that can enhance the anti-tumor immune response of T cells by blocking the interaction between PD-L1 and PD-1.

In China, durvalumab was approved by the National Food and Drug Administration (NMPA) in December 2019 for the treatment of stage III non-small cell lung cancer that failed platinum-based chemotherapy combined with radiotherapy. The launch of this drug provides Chinese patients with new treatment options, especially in the treatment of advanced lung cancer.

In short, as an important product of AstraZeneca in the field of tumor immunotherapy, durvalumab reflects the company's global R&D strength and market layout. Its launch in the Chinese market not only enriches the treatment options for Chinese patients, but also provides new impetus for AstraZeneca's business development in China.

Reference materials:https://www.imfinzi.com/